These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20370794)

  • 1. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D.
    Ertugrul DT; Yavuz B; Cil H; Ata N; Akin KO; Kucukazman M; Yalcin AA; Dal K; Yavuz BB; Tutal E
    Cardiovasc Ther; 2011 Apr; 29(2):146-52. PubMed ID: 20370794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?
    Yavuz B; Ertugrul DT; Cil H; Ata N; Akin KO; Yalcin AA; Kucukazman M; Dal K; Hokkaomeroglu MS; Yavuz BB; Tutal E
    Cardiovasc Drugs Ther; 2009 Aug; 23(4):295-9. PubMed ID: 19543962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
    Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
    Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group.
    Hongo M; Kumazaki S; Izawa A; Hidaka H; Tomita T; Yazaki Y; Kinoshita O; Ikeda U
    Circ J; 2011; 75(11):2660-7. PubMed ID: 21857142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
    Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
    BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.
    Bi YA; Qiu X; Rotter CJ; Kimoto E; Piotrowski M; Varma MV; Ei-Kattan AF; Lai Y
    Biopharm Drug Dispos; 2013 Nov; 34(8):452-61. PubMed ID: 23996477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment.
    Ott C; Raff U; Schneider MP; Titze SI; Schmieder RE
    Clin Res Cardiol; 2013 Apr; 102(4):299-304. PubMed ID: 23262496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical relevance of low-density-lipoproteins size modulation by statins.
    Rizzo M; Berneis K
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):205-17. PubMed ID: 16775666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
    Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro.
    Banfi C; Brioschi M; Lento S; Pirillo A; Galli S; Cosentino S; Tremoli E; Mussoni L
    J Thromb Haemost; 2011 Aug; 9(8):1608-19. PubMed ID: 21605334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
    Szabó M; Veres Z; Bátai-Konczos A; Kékesi O; Kis E; Szabó K; Jemnitz K
    Toxicol In Vitro; 2014 Sep; 28(6):1136-43. PubMed ID: 24909372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy.
    Laforest L; Moulin P; Souchet T; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Kieffer A; Van Ganse E
    Atherosclerosis; 2008 Aug; 199(2):368-77. PubMed ID: 18191135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
    Butterfield DA; Barone E; Mancuso C
    Pharmacol Res; 2011 Sep; 64(3):180-6. PubMed ID: 21536132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
    Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ
    Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.